- Email: [email protected]
Change of serum amyloid P component concentrations in women
Abstracts
Change of serum amyloid P component concentrations in women Katou M. Department of Obstetrics/Gynecology, Kanazawa University School of Medicine, Kanazawa ACTA OBSTET. GYNAECOL. JPN. 1996 48/7 (481-487) Serum amyloid P component (SAP) is a glycoprotein which was shown to be deposited in periarterial tissues and the glomerular basement membrane. It plays a part in aging, and the onset of amyloidosis and Alzheimer’s disease. In order to investigate the effects of sex steroids on the SAP level in menopausal women, SAP was purified. Anti-SAP was raised through the immunization of rabbits. The SAP level was assayed by micro single radial immunodiffusion. The SAP levels increased with aging from 1.1 f 0.8 mg/dl (mean + S.D.) to 5.08 f 1.31 mg/dl in women. The SAP level in males was significantly higher in the 15 to 50 year age group than in females of similar ages (P < 0.001). In the menstrual cycle, the SAP concentrations were significantly higher in the menstrual period (P < 0.05). During hormonal therapy in climacteric women, the SAP levels decreased significantly (P < 0.01) after Premarin treatment (from 5.66 + 1.45 mg/dl to 4.15 f 0.94 mg/dl) and increased (P < 0.001) after dehydroepiandrosterone therapy (from 4.00 ~fr 0.74 mg/dl to 6.07 + 1.14 mg/dl). From these findings, the SAP levels in humans were concluded to be age dependently increased, and higher in the menstrual period. Furthermore, it is suggested that a sex difference in SAP is concerned with the effect of estrogen fluctuation. 962373 14
Postmenopausal estrogen and progestin use and the risk of cardiovascular disease Grodstein F.; Stampfer M.J.; Manson J.E.; Colditz G.A.; Willett W.C.; Rosner B.; Speizer F.E.; Hennekens C.H. Channing Laboratory, 180 Longwood Ave., Boston, MA 02115 N. ENGL. J. MED. 1996 335/7 (453-461) Background: Estrogen therapy in postmenopausal women has been associated with a
153
decreased risk of heart disease. There is little information, however, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease. Methods: We examined the relation between cardiovascular disease and postmenopausal hormone therapy for up to 16 years of follow-up in 59 337 women from the Nurses’ Health Study, who were 30 to 55 years of age at base line. Information on hormone use was ascertained with biennial questionnaires. From 1976 to 1992, we documented 770 cases of myocardial infarction or death from coronary disease in this group and 572 strokes. Proportional hazards models were used to calculate relative risks and 95% confidence intervals, adjusted for confounding variables. Results: We observed a marked decrease in the risk of major coronary heart disease among women who took estrogen with progestin, as compared with the risk among women who did not use hormones (multivariate adjusted relative risk, 0.39; 95% confidence interval, 0.19-0.78) or estrogen alone (relative risk, 0.60; 95% confidence interval, 0.43-0.83). However, there was no significant association between stroke and use of combined hormones (multivariate adjusted relative risk, 1.09; 95% confidence interval, 0.66- 1.80) or estrogen alone (relative risk, 1.27; 95% confidence interval, 0.95- 1.69). Conclusions: The addition of progestin does not appear to attenuate the cardioprotective effects of postmenopausal estrogen therapy. 96248742
Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis Jonas H.A.; Kronmal R.A.; Psaty B.M.; Manolio T.A.; Meilahn E.N.; Tell G.S.; Tracy R.P.; Robbins J.A.; Anton-Culver H. Mother/Children> Health Study Ctr., La Trobe University, 463 Cardigan St, Carlton, Vie. 3053 ANN. EPIDEMIOL. 1996 6/4 (314-323) The cardioprotective effects of combined estrogenprogestin replacement therapy have been questioned. Therefore, we have compared carotid arterial wall thickening and the prevalence of carotid stenosis in elderly women (65 years old)
Change of serum amyloid P component concentrations in women Katou M. Department of Obstetrics/Gynecology, Kanazawa University School of Medicine, Kanazawa ACTA OBSTET. GYNAECOL. JPN. 1996 48/7 (481-487) Serum amyloid P component (SAP) is a glycoprotein which was shown to be deposited in periarterial tissues and the glomerular basement membrane. It plays a part in aging, and the onset of amyloidosis and Alzheimer’s disease. In order to investigate the effects of sex steroids on the SAP level in menopausal women, SAP was purified. Anti-SAP was raised through the immunization of rabbits. The SAP level was assayed by micro single radial immunodiffusion. The SAP levels increased with aging from 1.1 f 0.8 mg/dl (mean + S.D.) to 5.08 f 1.31 mg/dl in women. The SAP level in males was significantly higher in the 15 to 50 year age group than in females of similar ages (P < 0.001). In the menstrual cycle, the SAP concentrations were significantly higher in the menstrual period (P < 0.05). During hormonal therapy in climacteric women, the SAP levels decreased significantly (P < 0.01) after Premarin treatment (from 5.66 + 1.45 mg/dl to 4.15 f 0.94 mg/dl) and increased (P < 0.001) after dehydroepiandrosterone therapy (from 4.00 ~fr 0.74 mg/dl to 6.07 + 1.14 mg/dl). From these findings, the SAP levels in humans were concluded to be age dependently increased, and higher in the menstrual period. Furthermore, it is suggested that a sex difference in SAP is concerned with the effect of estrogen fluctuation. 962373 14
Postmenopausal estrogen and progestin use and the risk of cardiovascular disease Grodstein F.; Stampfer M.J.; Manson J.E.; Colditz G.A.; Willett W.C.; Rosner B.; Speizer F.E.; Hennekens C.H. Channing Laboratory, 180 Longwood Ave., Boston, MA 02115 N. ENGL. J. MED. 1996 335/7 (453-461) Background: Estrogen therapy in postmenopausal women has been associated with a
153
decreased risk of heart disease. There is little information, however, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease. Methods: We examined the relation between cardiovascular disease and postmenopausal hormone therapy for up to 16 years of follow-up in 59 337 women from the Nurses’ Health Study, who were 30 to 55 years of age at base line. Information on hormone use was ascertained with biennial questionnaires. From 1976 to 1992, we documented 770 cases of myocardial infarction or death from coronary disease in this group and 572 strokes. Proportional hazards models were used to calculate relative risks and 95% confidence intervals, adjusted for confounding variables. Results: We observed a marked decrease in the risk of major coronary heart disease among women who took estrogen with progestin, as compared with the risk among women who did not use hormones (multivariate adjusted relative risk, 0.39; 95% confidence interval, 0.19-0.78) or estrogen alone (relative risk, 0.60; 95% confidence interval, 0.43-0.83). However, there was no significant association between stroke and use of combined hormones (multivariate adjusted relative risk, 1.09; 95% confidence interval, 0.66- 1.80) or estrogen alone (relative risk, 1.27; 95% confidence interval, 0.95- 1.69). Conclusions: The addition of progestin does not appear to attenuate the cardioprotective effects of postmenopausal estrogen therapy. 96248742
Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis Jonas H.A.; Kronmal R.A.; Psaty B.M.; Manolio T.A.; Meilahn E.N.; Tell G.S.; Tracy R.P.; Robbins J.A.; Anton-Culver H. Mother/Children> Health Study Ctr., La Trobe University, 463 Cardigan St, Carlton, Vie. 3053 ANN. EPIDEMIOL. 1996 6/4 (314-323) The cardioprotective effects of combined estrogenprogestin replacement therapy have been questioned. Therefore, we have compared carotid arterial wall thickening and the prevalence of carotid stenosis in elderly women (65 years old)